EVQLV and Libera Bio collaborate to develop and deliver novel antibodies against intracellular cancer targets

• Antibodies can be designed to target very specific targets along cancer pathways

• Many of the best-validated intracellular cancer targets have been deemed ‘uncontrollable’ because large molecules cannot enter tumor cells spontaneously.

• EVQLV will design novel antibodies to target intracellular targets with high unmet needs

• Libera Bio will leverage its MPN® technology to deliver these antibodies to the target

New York, NY, USA and Santiago de Compostela, Spain – January 9, 2023 – EVQLV Inc. and Libera Bio SL have signed a collaboration agreement to jointly address intracellular targets, some of the most elusive cancer targets representing unmet medical needs.

Multiple pathways within cancer cells, such as the MAPK pathway or the “hedgehog pathway,” can create the conditions for tumors to develop, grow and evade the immune system. Interrupting the signals in these pathways at one or more points can slow the growth of tumors and inhibit their proliferation. Small molecules have been successfully developed for this purpose, but they can exhibit a significant level of toxicity and a lack of specificity. It has also been attempted to engineer antibodies to force them inside cancer cells, but it is a complex process, wrought with failure.

Libera Bio’s multifunctional polymer nanocapsules (MPN Technology®) offer an elegant way to deliver antibodies into cancer cells. The relevant antibodies are encapsulated in nanocapsules made of natural polymers of approx. 1/10,000 of a millimeter in diameter. Nanocapsules protect antibodies or other biological products from degradation. Actively or passively targeted, MPNs deliver these biological drugs to intracellular targets. A second active ingredient can be co-encapsulated in the MPN and delivered simultaneously to the cytosol.

Whole antibodies, close to their natural form, can be delivered this way. EVQLV has developed a proprietary AI-based system to optimize the design of these antibodies. EVQLV will computationally generate and rapidly screen a large set of different candidate antibodies against a prioritized list of intracellular targets.

EVQLV and Libera Bio will jointly develop new antibodies and their MPN delivery, with the aim of offering them to the largest pharmaceutical companies to conduct late-stage development and commercialisation.

“Combining computational antibody design with Libera’s new intracellular delivery technology allows us to push beyond the current limitations of antibodies, opening up a host of innovations for patients.” said Andrew Satz, co-founder and CEO of EVQLV. “We are thrilled to work alongside Libera Bio’s team of experts and continue our mission to accelerate the rate at which healing reaches those in need.”

“There are many intracellular targets that have so far been elusive to conventional treatments and that specially designed antibodies can efficiently address. We are delighted to work with EVQLV who offer a strong molecular biology background and cutting-edge technology to design such novel antibodies. We look forward to creating new options for cancer patients with unmet needs,” added Olivier Jarry, co-founder and CEO of Libera Bio.

About EVQLV.

EVQLV (www.evqlv.com) is a privately held US company headquartered in New York and Miami. EVQLV leverages advances in computation to revolutionize the design and development of therapeutic antibodies. EVQLV partners with companies at all stages of antibody development, performing de novo antibody design, antibody optimization, and designing the next generation of innovative immunotherapies.

Contact: Andrew Satz, CEO, [email protected]

About LiberaBio.

Libera Bio SL (www.liberabio.com) is a private Spanish company, spun off from the University of Santiago de Compostela (Galicia, Spain). Libera Bio aims to change cancer therapy by allowing biologics to cross the cell membrane and reach “uncontrollable” intracellular targets – the “Holy Grail” in oncology. He conducted preclinical studies on antibodies that address the frequent mutations of KRAS, a protein involved in a large number of cancers, especially pancreatic, colorectal and lung cancers. It is now preparing for enabling studies aimed at the authorization of a clinical trial.

Contact: Olivier Jarry, CEO, [email protected]

Contact with the media
Company Name: LiberaBio SL
contact person: Olivier Jarry, managing director
E-mail: Send an email
Village: Spain
Website: http://LiberaBio.com

Add a Comment

Your email address will not be published. Required fields are marked *